MIT Researchers Develop New Technique to Enhance CAR-T Cell Therapy Accessibility
Researchers at MIT have developed a groundbreaking technique aimed at enhancing the accessibility of CAR-T cell therapy, a treatment used for certain types of blood cancer. Currently, only about 5 percent of hospitals in the United States can generate and deliver CAR-T cells to patients, necessitating long-distance freezing and shipping of these cells. The new method focuses on protecting CAR-T cells from damage during freezing, which is crucial for their viability upon thawing.
The innovative approach minimizes the use of a chemical preservative traditionally employed in the freezing process. Instead of using the common cryoprotective agent dimethyl sulfoxide (DMSO), which must be removed before treatment and can compromise cell viability, the MIT team utilized a nontoxic antifreeze sugar. This allows for a more straightforward application: the cells can be thawed and injected directly without additional processing steps. Ana Jaklenec, a principal investigator at MIT’s Koch Institute for Integrative Cancer Research and one of the lead authors of the study published in Trends in Biotechnology, highlighted the potential for this technique to enable more cancer treatment centers to provide CAR-T cell therapy.
In their study, the researchers demonstrated that CAR-T cells preserved using this new method exhibited higher survival rates and were effective in treating lymphoma and glioblastoma in mouse models. The process of creating CAR-T cells involves isolating T cells from a patient’s blood, engineering them to express a chimeric antigen receptor (CAR) that targets specific proteins on cancer cells, and allowing them to proliferate before transfusion back into the patient. However, the majority of CAR-T cells are produced in centralized laboratories, and the need for freezing and shipping complicates the process.
The conventional method of cryopreservation involves treating the cells with DMSO to prevent ice crystal formation, which can damage cell membranes. Unfortunately, the removal of DMSO is a barrier for many hospitals lacking the necessary expertise. The MIT researchers sought to eliminate or significantly reduce the reliance on DMSO, thus enhancing the accessibility of CAR-T cell therapy.
To achieve this, they employed two sugars, trehalose and sucrose, known for their ability to help cells withstand cold temperatures. These sugars protect proteins from denaturation and inhibit ice crystal formation, a mechanism observed in certain Arctic organisms. The researchers used electroporation to introduce the sugars into the cells, which involved applying a brief electrical current to create temporary openings in the cell membranes.
While a small amount of DMSO was still required, it was not enough to necessitate removal. The results indicated that CAR-T cells and mesenchymal stem cells preserved with sugars had a higher survival rate during the freezing and thawing processes compared to those treated with DMSO. The study also highlighted the successful use of thawed CAR-T cells in treating non-Hodgkin’s lymphoma and glioblastoma in mice, with improved survival rates for those treated with the new preservation method.
Robert Langer, a senior author of the paper, emphasized the importance of innovation in preservation methods for living biotherapeutics, noting that traditional methods often compromise cell viability and function. The team hopes to collaborate with hospitals to integrate this new technique into existing CAR-T cell production and thawing processes, potentially leading to clinical trials in the future.
Vijay G. Sankaran, a pediatric hematologist and oncologist not involved in the study, expressed enthusiasm for the research's implications, stating that it could enhance the reliability and effectiveness of cell therapies by improving the survival rates of cells during freezing and thawing. He acknowledged that further validation of these findings in clinical settings would be necessary to fully realize the potential of this innovative approach.




